NeuraWorx Raises Seed Capital for Novel Brain Pacing Therapy

EXCELSIOR, MN – December 18, 2025 – Neurotechnology startup NeuraWorx Medical Technology, Inc. announced today the closing of an oversubscribed Seed funding round, a significant financial milestone aimed at advancing a novel therapy for central nervous system (CNS) disorders. The round was led by Nexus NeuroTech Ventures, a specialist investment firm, with participation from a strong syndicate including Foothill Ventures, Verge HealthTech Fund, and the Wisconsin Alumni Research Foundation (WARF).

The infusion of capital is earmarked to accelerate the development of the company’s first-in-class Cerebrovascular Pacing System™, a bioelectronic platform designed to address what some scientists call the brain's forgotten plumbing: the cerebrovascular and glymphatic systems. This funding signals growing investor confidence in tackling neurological diseases through fundamental physiological mechanisms rather than purely symptomatic treatments.

Targeting the Brain's Waste-Clearance Plumbing

At the heart of NeuraWorx's mission is a focus on a biological process that has only gained significant attention in the last decade: the glymphatic system. Functioning as the brain's dedicated waste-clearance network, it is responsible for flushing out metabolic byproducts, such as amyloid-beta and tau proteins, which are famously implicated in Alzheimer's disease. A growing body of research suggests that dysfunction in this system—along with the related cerebrovascular network that helps drive it—is a foundational element in a host of neurodegenerative and neuropsychiatric conditions.

While many pharmaceutical efforts have focused on targeting these toxic proteins after they have already accumulated, NeuraWorx is taking a different approach. The company aims to restore the function of the clearance system itself. Its Cerebrovascular Pacing System™ is a proprietary bioelectronic platform designed to enhance brain fluid dynamics, effectively helping the brain to clean itself more efficiently. This upstream, mechanistic approach could represent a paradigm shift in treating a wide range of debilitating illnesses.

The novelty and scientific rigor of this strategy were key factors for investors. “NeuraWorx is addressing a foundational and underexplored mechanism in brain health: cerebrovascular and glymphatic dysfunction, which is increasingly implicated in neurodegenerative and neuropsychiatric diseases,” said John Propst, PhD, MBA, Principal at Nexus NeuroTech Ventures. “What differentiated this opportunity for Nexus was the strength of the underlying physiology, the clarity of the mechanistic hypothesis, and a robust chain of preclinical and emerging clinical evidence supporting translatability.”

A Vote of Confidence from Specialized Investors

The leadership of Nexus NeuroTech Ventures in the funding round is particularly noteworthy. As a firm singularly focused on pioneering technologies for brain disorders, its investment serves as a powerful validation of NeuraWorx's potential. Nexus's portfolio includes a range of companies tackling neurological conditions from various angles, including wearable neuromodulation and AI-driven diagnostics, indicating a deep understanding of the sector's complexities and opportunities.

This strategic alignment provides NeuraWorx not just with capital, but with a partner possessing deep clinical and technical expertise. The global neurotechnology market is projected to grow from approximately $15 billion in 2024 to over $50 billion by 2034, driven by an aging global population and the rising prevalence of CNS disorders. Investors are increasingly looking for platform technologies that can address multiple conditions, and NeuraWorx's focus on a fundamental mechanism like glymphatic function fits that profile.

“This funding validates our science and accelerates our mission to transform brain health for everyone,” said Chris Minar, CEO and Co-Founder of NeuraWorx. He emphasized the immediate impact of the capital, stating, “We are immediately scaling our team to attract world-class talent in neuroscience, clinical development, and regulatory affairs—people who share our vision of bringing the first-in-class Cerebrovascular Pacing System™ to patients as quickly and safely as possible.”

From University Lab to Commercial Lifeline

The story of NeuraWorx is also a prime example of the critical pathway from academic discovery to commercial enterprise. The company's core technology was originally developed at the University of Wisconsin-Madison, a powerhouse in biomedical engineering and neuroscience research. This academic origin lends a strong foundation of scientific credibility to the venture.

Integral to this transition is the Wisconsin Alumni Research Foundation (WARF), which participated in the seed round. WARF is the designated patent and licensing organization for the University of Wisconsin-Madison and has a long history of helping transform university research into world-changing products and companies. Its investment underscores a long-term belief in the technology's potential and represents a successful culmination of the tech transfer process, which aims to ensure that taxpayer-funded research delivers tangible benefits to society.

This journey from a university laboratory to a clinical-stage company with significant venture backing highlights a vital ecosystem for medical innovation, where foundational science is nurtured and then propelled into the commercial sphere to address urgent patient needs.

The Long Road from Clinical Stage to Patient Care

Despite the promising technology and fresh funding, the path ahead for NeuraWorx is both complex and lengthy. As a “clinical-stage” company, it has advanced beyond initial preclinical work but must now navigate the rigorous and costly process of human clinical trials to prove its device is both safe and effective. The company's focus on hiring experts in clinical development and regulatory affairs is a clear acknowledgment of this impending challenge.

Novel bioelectronic devices, particularly those targeting the brain, typically fall under the FDA's most stringent regulatory category, Class III. This pathway requires extensive data and can take many years to complete. The history of neurotechnology is filled with groundbreaking ideas that took decades to reach widespread clinical use. However, the immense unmet need for effective CNS therapies is a powerful motivator. Neurological conditions are the leading cause of disability worldwide, affecting over one in three people and placing an enormous burden on patients, families, and healthcare systems.

For the millions suffering from conditions like Alzheimer's, Parkinson's, and severe depression, the slow and deliberate pace of medical innovation can be frustrating. Yet, it is precisely this methodical, evidence-based approach that NeuraWorx and its investors are now equipped to pursue, carrying the hope of one day restoring the brain's own ability to heal itself.